Amjad Ali

7834042, Nov 16, 2010

Dec 11, 2007

12/312225

Iyassu K. Sebhat - Jersey City NJ, US
Michael Man-chu Lo - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Amjad Ali - Freehold NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/41
C07D 257/04

514381, 548250

A compound having the structure (Formula I), wherein Y is —Y—Y—Y—Y—Y—; Yis C(O) or C(RR); Yis O, C(O), P(O)(OH) or CH, provided that when Yis C(O), Yis not C(O); Ris selected from the group consisting of hydrogen and Calkyl; Ris selected from the pup consisting of hydrogen, Calkyl, and —OC(O)Calkyl; Yis O, C(O) or CH, provided that when Yis C(O), then Yis not C(O), and further provided that when Yis O, then Yis not O; Yis O or CHor is absent, provided that when Yis O, then Yis not O; Y5 is —(CH)—(X)—(CH)— or is absent; X is —O— or —CRR—; and Rand Rare independently selected from the group consisting of hydrogen and C-Calkyl; or a pharmaceutically acceptable salt thereof, which is useful for treating hypertension.

7880014, Feb 1, 2011

Dec 11, 2007

12/000247

Iyassu K. Sebhat - Jersey City NJ, US
Michael Man-chu Lo - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Amjad Ali - Freehold NJ, US
Chris Franklin - Keasbey NJ, US
Nicoletta Almirante - Milan, IT
Laura Storoni - Cesano Maderno, IT
Silvia Stefanini - San Donato Milanese, IT

Merck Sharp & Dohme Corp. - Rahway NJ
NiCox S.A. - Valbonne

C07D 257/00
C07D 403/00

548250, 5483001

A compound having the structure.

20100152259, Jun 17, 2010

Dec 11, 2007

12/516482

Iyassu K. Sebhat - Jersey City NJ, US
Michael Man-chu Lo - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Amjad Ali - Freehold NJ, US
Chris Franklin - Rahway NJ, US
Nicoletta Almirante - Milano, IT
Laura Storoni - Cesano Maderno, IT
Silvia Stefanini - San Donato Milanese, IT

Merck & Co Inc. - Rahway NJ
NICox S.A. - Valbonne

C07D 403/10
A61K 31/4184
A61P 9/12

514381, 514394, 548253, 5483054

A compound having the structure (Formula I), wherein R an angiotensin receptor antagonist active group, Y is Y—Y—Y—Y—Y. Yis C(RR); Ris selected from the group consisting of hydrogen and Calkyl; Ris selected from the group consisting of hydrogen, Calkyl, and -0C(0)Calkyl; Yis O or CH; Yis C(O) or CH; Yis O or CH; Y5 is —(CH2)—(X)—CH)— or is absent; X is —O— or —CRR—; and Rand Rare independently selected from the group consisting of hydrogen and C-Calkyl; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.

20140045819, Feb 13, 2014

Apr 20, 2012

14/112945

Scott B. Hoyt - Hoboken NJ, US
Whitney Lane Petrilli - Jersey City NJ, US
Clare London - Chatham NJ, US
Yusheng Xiong - Plainsboro NJ, US
Jerry Andrew Taylor - Trenton NJ, US
Amjad Ali - Freehold NJ, US
Michael Man-Chu Lo - Edison NJ, US
Timothy J. Henderson - Edison NJ, US
Qingzhong Hu - Saarbrucken, DE
Rolf Hartmann - Saarbrucken, DE
Lina Yin - Saarbrucken, DE
Ralf Heim - Wiesbaden, DE
Emmanuel Bey - Forbach, DE
Rohit Saxena - Lucknow, IN
Swapan Kumar Samanta - Nandini Layout, IN
Bheemashankar A. Kulkarni - Rajajinagar, IN

ElexoPharm GmbH - Saarbrucken
SCHERING CORPORATION - Rahway NJ

C07D 487/04
C07D 471/04

51421021, 546 82, 514293, 540578, 51421402

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

20230054411, Feb 23, 2023

Nov 26, 2019

17/294836

Yonglian ZHANG - Kenilworth NJ, US
Amjad ALI - Kenilworth NJ, US
Jared CUMMING - Winchester MA, US
Duane DEMONG - Boston MA, US
Qiaolin DENG - Kenilworth NJ, US
Thomas H. GRAHAM - Boston MA, US
Elisabeth HENNESSY - Boston MA, US
Matthew A. LARSEN - Boston MA, US
Kun LIU - Boston MA, US
Ping LIU - Boston MA, US
Umar Faruk MANSOOR - Boston MA, US
Jianping PAN - Kenilworth NJ, US
Christopher W. PLUMMER - Kenilworth NJ, US
Aaron SATHER - Boston MA, US
Uma SWAMINATHAN - Boston MA, US
Huijun WANG - Westfield NJ, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/519
A61K 39/395
C07D 471/04
C07D 519/00
A61K 31/55

In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2and/or A2receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2receptor and/or the adenosine A2receptor.

20160214997, Jul 28, 2016

Aug 25, 2014

14/914843

Amjad ALI - Rahway NJ, US
Gioconda V. GALLO - Rahway NJ, US
Timothy J. HENDERSON - Boston MA, US
Rongze KUANG - Rahway NJ, US
Yeon-Hee LIM - Rahway NJ, US
Michael Man-Chu LO - Rahway NJ, US
Edward METZGER - Somerset NJ, US
Manuel de Lera RUIZ - West Point PA, US
Andrew STAMFORD - Rahway NJ, US
Paul TEMPEST - Shanghai, CN
Brent WHITEHEAD - Kinilworth NJ, US
Heping WU - Rahway NJ, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 519/00
C07D 491/147

The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of Areceptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which Areceptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which Areceptors are involved.

20160194330, Jul 7, 2016

Dec 20, 2013

14/655572

Amjad ALI - Rahway NJ, US
Michael Man-Chu LO - Rahway NJ, US
Yeon-Hee LIM - Rahway NJ, US
Andrew STAMFORD - Rahway NJ, US
Rongze KUANG - Rahway NJ, US
Paul TEMPEST - Shanghai, CN
Younong YU - Rahway NJ, US
Michael BERLIN - Flemington NJ, US
Pauline TING - Rahway NJ, US
Gang ZHOU - Rahway NJ, US
Tao YU - Rahway NJ, US
Christopher BOYCE - Rahway NJ, US
Joseph Michael KELLY - Rahway NJ, US
Jayaram TAGAT - Kenilworth NJ, US
Junying ZHENG - Rahway NJ, US
Xianhai HUANG - Rahway NJ, US
Wei ZHOU - Rahway NJ, US
Jae-Hun KIM - Rahway NJ, US
Nicolas ZORN - Rahway NJ, US
Dong XIAO - Kenilworth NJ, US
Gioconda V. GALLO - Rahway NJ, US
Walter WON - Rahway NJ, US
Heping WU - Rahway NJ, US
Rajan ANAND - Rahway NJ, US
- New Jersey NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 487/04
C07D 487/18
C07D 487/08
C07D 513/04

Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

20150225365, Aug 13, 2015

Oct 2, 2013

14/433441

Amjad ALI - Rahway NJ, US
Man-Chu Michael - Rahway NJ, US
Edward METZGER - Rahway NJ, US
Lina YIN - Saarbrücken, DE
Rolf HARTMANN - Saarbrücken, DE
Qingzhong HU - Saarbrücken, DE
Ralf HEIM - Saarbrücken, DE
Christina ZIMMER - Saarbrücken, DE
- Rahway NJ, US
- Saarbrücken, DE

ElexoPharm GmbH - Saarbrucken
Merck Sharp & Dohme Corp. - Rahway NJ

C07D 401/04
C07D 409/14

This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.